LEAMINGTON, ON, March 21, 2018 /CNW/ - Aphria Inc.
("Aphria" or the "Company") (TSX: APH and
US OTC: APHQF) today announced that it has signed an exclusive
supply agreement with an Argentinan based pharmaceutical import and
distribution company, which is licensed to import, sell and
distribute medical products and derivatives in Argentina. The
importer is currently securing an import license for cannabis in
Argentina.
"We are excited to enter the Argentinian market through this
initial supply agreement," said Vic
Neufeld, CEO of Aphria. "We see tremendous potential for
medical cannabis in several emerging markets in South America, including Argentina. As the leading low-cost supplier of
high-quality medical cannabis, Aphria will continue to expand its
global leadership through strategic investments, partnerships and
exclusive agreements such as this one."
Under the terms of the agreement, Aphria will be the exclusive
supplier of cannabis products to the importer for the Argentine
market. At the importer's request, financial terms and the name of
the importer of the agreement are not being released.
We Have a Good Thing Growing.
About Aphria
Aphria Inc., one of Canada's
lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington,
Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight
allowing for the most natural growing conditions available. Aphria
is committed to providing pharma-grade medical cannabis, superior
patient care while balancing patient economics and returns to
shareholders.
For more information, visit: www.aphria.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated margins, expectations with respect to actual production
volumes, expectations with volumes or prices under the agreement,
expectations with respect to the importer's ability to secure an
import license for cannabis, expectations for future growing
capacity and costs, the completion of any capital project or
expansions, and expectations with respect to future production
costs. Forward-looking statements necessarily involve known and
unknown risks, including, without limitation, risks associated with
general economic conditions; adverse industry events; marketing
costs; loss of markets; future legislative and regulatory
developments involving medical cannabis; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
medical cannabis industry in Canada and Argentina generally, income tax and regulatory
matters; the ability of Aphria to implement its business
strategies; competition; crop failure; currency and interest rate
fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.